Neena Brizmohun
Deputy Editor

Neena has been covering regulatory, business and market access developments that impact pharmaceutical and medical device companies since 1997. She explores the challenges and opportunities that developments worldwide introduce for industry and regulators. Her areas of expertise include regulatory schemes for getting products to market faster. Neena's other specialist areas include new medicines coming to market in the EU, pricing and reimbursement, clinical trials, real-world evidence, post-marketing safety monitoring, transparency policies relating to the publication of trial data, and global harmonization initiatives for pharma and medtech.
Latest From Neena Brizmohun
EU CHMP Opinions and MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
New EU Filings
Omaveloxolone, Reata Pharmaceuticals’s orphan drug for treating patients with Friedreich’s ataxia, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
UK Guidance Tackles Social Media ‘Compliance Headache’ For Pharma
Announcing product milestones and liking LinkedIn posts are just some of the topics addressed in a long-awaited guidance that deals with the challenges prescription drug makers face in the UK when using social media.
CTIS: EU Industry Welcomes ‘Landmark Moment’ But Says Issues Still Need Addressing
EFPIA acknowledges that while the mandatory use of the EU Clinical Trials Information System from today is a significant milestone, it says the usability and functionality of the system need to be enhanced and there are also issues with the Clinical Trials Regulation that need to be fixed.
‘Quick Guide’ To Help EU Clinical Trial Sponsors As CTIS Hits 31 January Milestone
Just a day before it became mandatory to use the single-portal Clinical Trial Information System, the European Commission published concise advice for sponsors and investigators who want to conduct trials in Europe.
Ophthalmic Bevacizumab & CRISPR-Based Gene Therapy Among Latest EU Filings
Investigational drugs from Outlook Therapeutics and Vertex/CRISPR could become first-of-their-kind products if they win marketing approval.